TD Cowen Maintains Buy Rating on Gilead Sciences

TD Cowen analyst Tyler Van Buren has reaffirmed a 'Buy' rating on Gilead Sciences (GILD), maintaining a price target of $160. This decision reflects the firm's consistent outlook on Gilead's performance and market position, with no changes to the previous investment thesis or target price.